Sensei Biotherapeutics Reports Q1 2025 Results; Clinical Progress for Solnerstotug in PD-(L)1 Resistant Tumors

Sensei Biotherapeutics, Inc.

2025-Q1 EPS reported -$0.27

Net loss of $6.9 million for Q1 2025, down from $8.0 million in Q1 2024.
Cash, cash equivalents and marketable securities were $34.3 million as of March 31, 2025, expected to fund operations into Q2 2026.
Dose expansion enrollment complete with 63 patients; full Phase 1/2 data expected by year-end 2025.
Favorable clinical activity observed in PD-(L)1 resistant 'hot' tumors, with response rates nearly three times higher than typical rechallenge.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.